Benjamin Brakel

Mr. Benjamin Brakel


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
BBBenjamin Brakel
Benjamin Brakel
ASAli Saleh
Ali Saleh
MSMelissa Saleh
Melissa Saleh
PMPetar Miletic
Petar Miletic
SSSabra Salim
Sabra Salim
CCChirayu R Chokshi
Chirayu R Chokshi
BTFC travel award recipient Glioblastoma (GBM) is a lethal brain tumor. Despite intensive standard of care (SoC) consisting of surgical resection followed by radiation therapy (RT) and chemotherapy with temozolomide (TMZ), tumor relapse is inevitable with a median overall survival of 14.6 months. Therapeutic failure is attributable to the presence of GBM stem-like cells (GSCs), which are highly resistant to genotoxic therapies, self-renew and differentiate to perpetuate intra-tumoral heterogeneity, and seed tumor recurrence. However, no clinical advances have been made in overcoming resistance to therapy in GSCs, and the mechanisms underlying this resistance remain largely unknown. With the advent of CRISPR-Cas9 technology, functional genetic screens have been used to identify genes that regulate survival and sensitivity to TMZ in GSCs. However, they have not been applied to SoC and a comprehensive set of modulators governing resistance to combination treatment has yet to be determined. Here, we perform genome-wide CRISPR-Cas9 screening in patient-derived treatment-sensitive and treatment-resistant GSC models under normal growth conditions or while exposed to in vitro chemoradiotherapy. By integrating genetic dependencies and treatment-based conditional genetic interactions modulating sensitivity to SoC, we identify flap endonuclease 1 (FEN1) as a driver of GSC survival and therapy resistance in treatment-resistant GBM. Functionally, FEN1 inhibition demonstrates specific killing and synergy with TMZ in treatment-resistant GSCs while sparing healthy neural stem cells (NSCs) and treatment-sensitive GSCs. At the molecular level, FEN1 inhibition induces DNA damage and repair specifically in treatment-resistant GBM, posing FEN1 as an attractive therapeutic target in this population of GBM patients which SoC currently fails.

23 November 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
NTNoah Tregobov
Noah Tregobov
MKMichal Krolikowski
Michal Krolikowski
RDRyan Dragoman
Ryan Dragoman
BBBenjamin Brakel
Benjamin Brakel
PMPeter L. Munk
Peter L. Munk
MHManraj K.S. Heran
Manraj K.S. Heran
Primary spinal osseous tumors are relatively rare, comprising ~5–10% of spinal bone neoplasms, whereas metastases account for the vast majority of spinal lesions. Patients commonly present with insidious back pain, sometimes with a focal mass, and constitutional symptoms are uncommon early in the disease course. As clinical features are often nonspecific and may overlap with degenerative, infectious, and metastatic disease, imaging plays an important role in lesion identification, characterization, and treatment planning. Computed tomography helps to define osseous architecture and matrix characteristics. Magnetic resonance imaging can assess marrow involvement, soft tissue extension, neural compression and intra-canal disease, and tumor vascularity. Together, advanced imaging modalities guide further workup, optimize biopsy planning, inform prognostic assessment and therapeutic decision-making, and anticipate mechanical instability or neural compromise. This narrative pictorial review synthesizes radiographic, CT, and MRI appearances of primary spinal tumors across major histologic lineages (e.g., osteogenic, chondrogenic, notochordal, vascular), illustrated with representative cases. We correlate imaging with clinical presentation to distinguish typical from atypical variants and highlight mimics and pitfalls with implications for diagnostic interpretation and management.